X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Merger will focus on developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Notable Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 16, 2023
Details:
The Merger will create a clinical-stage therapeutic platform company developing new precision medicines through Notable’s proprietary PPMP. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis in cancer cells.
Lead Product(s): Volasertib
Therapeutic Area: Oncology Product Name: NBL-001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Notable Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
OVAL was an international, Phase 3, randomized, double-blind, placebo-controlled, clinical trial comparing a combination of ofra-vec (ofranergene obadenovec; VB-111) plus paclitaxel to placebo plus paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
VBL is advancing drug development program that is exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases.
Lead Product(s): VB-601
Therapeutic Area: Oncology Product Name: VB-601
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Ofranergene Obadenovec is an investigational anti-cancer, gene-therapy agent in development to treat a wide range of solid tumors. Ofra-vec is a unique biologic agent designed to use a dual mechanism to target solid tumors.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Phase 3 OVAL trial enrolled 409 patients globally, comparing a combination of VB-111 (GOG-3018), a unique biologic agent designed to use a dual mechanism to target solid tumors, and paclitaxel to placebo plus paclitaxel, in adult patients with ovarian cancer.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The funds from the EIC will be used to support clinical development, Chemistry Manufacturing and Controls (CMC), and pre-commercialization activities and will support the ongoing Phase 3 OVAL registration-enabling clinical trial of ofra-vec (VB-111) in ovarian cancer.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EIC Accelerator
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 20, 2021
Details:
The OVAL trial evaluating VB-111 in ovarian cancer is planned to enroll approximately 400 patients globally and nearly 80% of patients have already been recruited.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
Details:
OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum resistant ovarian cancer.
Lead Product(s): Ofranergene Obadenovec,Paclitaxel
Therapeutic Area: Oncology Product Name: VB-111
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
The claims in the granted patent cover the use of such anti-MOSPD2 antibody/antibody fragment to treat a wide range of cancers which express MOSPD2, including solid tumors and hematological cancers.
Lead Product(s): Anti-MOSPD2 monoclonal antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
